Cumberland Pharmaceuticals Q1 net loss $1.9M; revenue $8.5M

CUMBERLAND PHARMACEUTICALS INC

2024-Q1 EPS reported -$0.14 revenue$8,497,701

Net revenue $8.5M; Kristalose $3.2M, Sancuso $1.8M, Vibativ $1.6M, Caldolor $1.5M.
Net loss $1.9M ($0.14/share); adjusted loss $0.6M ($0.05/share).
Cash $19M, total assets $82M, liabilities $54M, equity $27M.
Caldolor highlighted in NOPAIN Act; CMS decision pending for 2025 Medicare reimbursement.
Ifetroban enrollment underway for Idiopathic Pulmonary Fibrosis trial (128 patients).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.

Period: the three months ended March 31, 2024
Revenue: $8.5 million
Result: reported results

Exact text from the filing

Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-24-021185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.